title: Posterior vitreous detachment following intravitreal drug injection.
abstract: BACKGROUND
  To evaluate the incidence of posterior vitreous detachment (PVD) induced by intravitreal injection of different intravitreal drugs.
  
  
  METHODS
  This prospective observational study included 61 patients (61 eyes) with different underlying retinal diseases: exudative age-related macular degeneration (n = 47), cystoid macular edema (CME) after retinal vein occlusion (n = 8), and CME of other origin (n = 6). Bevazicumab (1.25 mg) was injected into 25 eyes, ranibizumab (0.5 mg) into 27 eyes, triamcinolone (4 mg) into six eyes, and a combination of bevacizumab and triamcinolone into three eyes. Patients with initial PVD were excluded. Patients were followed for at least 4-6 weeks after their last injection by Fourier-domain OCT, fundus biomicroscopy and ultrasound B-examination.
  
  
  RESULTS
  Overall, 15 of 61 eyes developed a PVD after intravitreal injection (n = 6 after ranibizumab, n = 7 after bevacizumab and n = 2 after triamcinolon) within a mean follow-up period of 11.1 weeks. PVD occurred in three eyes after the first injection, in three eyes after the second, and in seven eyes after the third injection. Incidence of PVD correlated with increasing age.
  
  
  CONCLUSIONS
  Intravitreal injection of commonly-used drugs seems to induce posterior vitreous detachment, which may thus influence the outcome of the underlying disease.
authors: Augenklinik der Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany. ugeck@web.de
authors: Ulrich
authors: U
authors: Geck
authors: Nicole
authors: N
authors: Pustolla
authors: Husnia
authors: H
authors: Baraki
authors: Abed
authors: A
authors: Atili
authors: Nicolas
authors: N
authors: Feltgen
authors: Hans
authors: H
authors: Hoerauf
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use; D000068258:Bevacizumab; D005260:Female; D005500:Follow-Up Studies; D005583:Fourier Analysis; D006801:Humans; D015994:Incidence; D058449:Intravitreal Injections / Q000009:adverse effects*; D008269:Macular Edema / Q000188:drug therapy; D008297:Male; D033401:Microscopy, Acoustic; D008875:Middle Aged; D011446:Prospective Studies; D000069579:Ranibizumab; D012170:Retinal Vein Occlusion / Q000188:drug therapy; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use; D020255:Vitreous Detachment / Q000175:diagnosis / Q000209:etiology*; D057135:Wet Macular Degeneration / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide; D000069579:Ranibizumab
references: Am J Ophthalmol. 2007 Nov;144(5):741-746
references: 17884003
references: Doc Ophthalmol. 2004 Nov;109(3):249-53
references: 15957610
references: Retina. 2010 Jul-Aug;30(7):1122-7
references: 20616687
references: Graefes Arch Clin Exp Ophthalmol. 1994 Feb;232(2):67-70
references: 8157177
references: Acta Ophthalmol Scand. 1999 Apr;77(2):170-5
references: 10321533
references: Ophthalmology. 2010 Jun;117(6):1087-1093.e3
references: 20299105
references: Jpn J Ophthalmol. 2000 Jan-Feb;44(1):91-3
references: 10698032
references: Ophthalmologica. 2009;223(3):172-6
references: 19174614
references: Ophthalmologe. 1996 Dec;93(6):660-5
references: 9081520
references: Retina. 2000;20(2):115-20
references: 10783942
references: Ophthalmology. 1982 Dec;89(12):1502-12
references: 7162795
references: N Engl J Med. 2012 Aug 16;367(7):606-15
references: 22894573
references: Ophthalmology. 1988 Oct;95(10):1335-9
references: 3226682
references: Klin Oczna. 2010;112(7-9):210-2
references: 21117364
references: Eye (Lond). 1987;1 ( Pt 2):254-62
references: 3308528
references: Am J Ophthalmol. 2008 Aug;146(2):218-227
references: 18538742
references: Acta Ophthalmol. 2008 Aug;86(5):470-81
references: 18537930